Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
نویسندگان
چکیده
منابع مشابه
Cytotoxic T-lymphocyte-associated antigen-4.
Cancer immunotherapy relies on the ability of the immune system to target tumor-specific antigens to generate an immune response. This initial response requires both binding of the MHC/antigen peptide to T-cell receptor complex, along with a second costimulatory signal created by the binding of CD28 on the T cell, with B7 located on the antigen-presenting cell. Regulatory checkpoints, such as c...
متن کاملCytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
The relationship between cancer and the immune system is complex and provides unique therapeutic opportunities. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulatory molecule that suppresses T cell effector function following initial activation by costimulatory signals. Fully human monoclonal antibodies targeting CTLA-4 have been shown to increase T cell function and antitumor responses in ...
متن کاملCytotoxic T lymphocyte antigen - 4 and immune checkpoint blockade
Introduction The immune system is an important defense against the development and progression of cancer (1). Historically, there has been a waxing and waning enthusiasm for immune therapies to treat cancer due to limited efficacy. Immunotherapies, such as IL-2 and adoptive transfer of autologous tumor-infiltrating lymphocytes, can induce durable tumor responses in a subset of patients, leading...
متن کاملEnterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
PURPOSE Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) is an inhibitory receptor on T cells. Knocking out CTLA4 in mice causes lethal lymphoproliferation, and polymorphisms in human CTLA4 are associated with autoimmune disease. Trials of the anti-CTLA4 antibody ipilimumab (MDX-010) have resulted in durable cancer regression and immune-mediated toxicities. A report on the diagnosis, patholo...
متن کاملTransient hypophysitis after cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade.
C T LYMPHOCYTE-associated antigen 4 (CTLA4) blockade using the human anti-CTLA4 monoclonal antibody CP-675,206 has antitumor activity in melanoma (1). Blockade of CTLA4 binding to its B7 ligands results in disruption of peripheral immune tolerance and enhanced T cell activation (2), which can cause secondary autoimmune endocrinopathies, including hypophysitis and thyroiditis (1, 3, 4). We herei...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer
سال: 2015
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2015.08.012